Recent Colon Cancer News and Updates Patients and Survivors May Have Missed

There have been multiple updates in the field of colorectal cancer over the past several weeks. In honor of Colorectal Cancer Awareness Month, CURE® looks back at some of the latest news and updates affecting patients with that cancer type.

• Patients with rectal cancer who maintain a clinical complete response – meaning they are found to have no evidence of disease – after three years, may not need as frequent surveillance after that point, due to a decreased chance of regrowth and metastases. READ MORE.
• As the incidence of colorectal cancer in patients under age 50 rises, overall health-related quality of life among younger survivors is declining, with longer treatment taking a toll on social and functional well-being. READ MORE.
• Danielle Ripley-Burgess, a two-time colon cancer survivor, discusses why she wrote a book about her journey and how her experience strengthened her faith. READ MORE.
• Sending a text message reminder to participants about their upcoming fecal immunochemical test improved previously poor adherence rates for colorectal cancer screening. READ MORE.
• In the final analysis of the phase 2 TASCO1 trial, patients who received the combination of Lonsurf (trifluridine/tipiracil) and Avastin (bevacizumab) reached a median overall survival of 22.31 months compared with 17.67 months in those who received Xeloda (capecitabine) and Avastin. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.